A detailed history of Ubs Asset Management Americas Inc transactions in Regenxbio Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 66,078 shares of RGNX stock, worth $503,514. This represents 0.0% of its overall portfolio holdings.

Number of Shares
66,078
Previous 70,958 6.88%
Holding current value
$503,514
Previous $830,000 16.51%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.49 - $14.39 $51,191 - $70,223
-4,880 Reduced 6.88%
66,078 $693,000
Q2 2024

Aug 13, 2024

BUY
$11.51 - $21.53 $373,085 - $697,873
32,414 Added 84.1%
70,958 $830,000
Q3 2023

Nov 13, 2023

BUY
$16.46 - $19.99 $217,881 - $264,607
13,237 Added 52.31%
38,544 $634,000
Q1 2023

May 15, 2023

SELL
$18.08 - $24.55 $166,173 - $225,639
-9,191 Reduced 26.64%
25,307 $478,000
Q4 2022

Feb 14, 2023

SELL
$20.4 - $24.73 $40,738 - $49,385
-1,997 Reduced 5.47%
34,498 $782,000
Q2 2022

Aug 12, 2022

SELL
$19.35 - $35.04 $25,058 - $45,376
-1,295 Reduced 3.43%
36,495 $901,000
Q3 2021

Nov 15, 2021

SELL
$29.09 - $45.68 $48,085 - $75,509
-1,653 Reduced 4.19%
37,790 $1.58 Million
Q2 2021

Aug 16, 2021

BUY
$32.46 - $40.48 $84,785 - $105,733
2,612 Added 7.09%
39,443 $1.53 Million
Q1 2021

May 14, 2021

BUY
$33.61 - $49.95 $334,117 - $496,552
9,941 Added 36.97%
36,831 $1.26 Million
Q2 2020

Aug 14, 2020

BUY
$27.75 - $43.44 $125,568 - $196,566
4,525 Added 20.23%
26,890 $990,000
Q1 2020

May 15, 2020

SELL
$21.5 - $54.2 $2.12 Million - $5.35 Million
-98,759 Reduced 81.54%
22,365 $724,000
Q4 2019

Feb 14, 2020

BUY
$34.54 - $44.87 $24,834 - $32,261
719 Added 0.6%
121,124 $4.96 Million
Q3 2019

Nov 14, 2019

BUY
$31.84 - $50.88 $22,001 - $35,158
691 Added 0.58%
120,405 $4.29 Million
Q2 2019

Aug 15, 2019

BUY
$42.0 - $59.29 $31,584 - $44,586
752 Added 0.63%
119,714 $0
Q1 2019

May 14, 2019

BUY
$40.82 - $62.45 $393,423 - $601,893
9,638 Added 8.82%
118,962 $0
Q4 2018

Feb 13, 2019

SELL
$39.11 - $75.15 $251,359 - $482,989
-6,427 Reduced 5.55%
109,324 $4.59 Million
Q3 2018

Nov 14, 2018

BUY
$65.0 - $82.15 $6.74 Million - $8.51 Million
103,628 Added 854.8%
115,751 $0
Q2 2018

Aug 14, 2018

BUY
$27.2 - $74.35 $329,745 - $901,345
12,123 New
12,123 $0

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $329M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.